Management Forum Logo

Presented by
Management Forum

Drafting Effective Pharmaceutical Patents Training Course

Drafting successful pharmaceutical patents is complex and there are many pitfalls and risks to be aware of. You need to ensure you’re maximising the protection for your, and your client’s, pharmaceutical inventions thorough both primary and secondary pharmaceutical patents.

3-6 September 2024 »
from £999

Need help?  Enrol or reserve

Course overview

The area of pharmaceutical patents is highly complex with many pitfalls to be aware of and to know how to mitigate against. During this course the expert faculty will take you through the key differences between the European and US systems and how these can impact your patents. They will explore the latest strategies and give you useful insights and practical solutions to your drafting issues. By understanding the importance of aligning your patent and regulatory strategies, you will improve your pharmaceutical claim drafting skills to the best advantage.

The practical claim drafting exercises included in the course will give you an opportunity to get to grips with the information in a safe environment and under the guidance of the expert trainers. They will help embed what you have learnt so that it can be taken back to the workplace and put into practice.

As well as receiving inside knowledge and top tips and advice from the highly experienced speaker, the course also provides a valuable opportunity to network with others in similar roles from different companies. By attending, you can discuss your challenges with colleagues and our expert faculty and find solutions to your questions.

Key topics covered in this intensive training programme include:

  • Drafting primary patents and secondary patents
  • Key differences between drafting for Europe versus the US
  • Claim drafting strategies for antibodies and other biologics
  • Drafting claims that ‘follow the label’
  • Drafting patent applications with sufficient supporting data – how much is enough?
  • Aligning your patent strategy with regulatory issues

This course is part of our collection of IP & Patents Training Courses.

Benefits of attending

By attending this course you will:

  • Understand how to draft primary patents in the small molecule and biologics fields
  • Ensure comprehensive protection for innovations from genetic sequences through to therapeutic applications
  • Learn how to protect medical use claims – first, second and Swiss-type
  • Get to grips with drafting claims for infringement
  • Consider regulatory issues and data protection
  • Enhance your knowledge of the data needed to support patent applications
  • Recognise the importance of correct data in avoiding inequitable conduct
  • Boost your knowledge of secondary patents and their benefits

Who should attend?

This course has been specially designed for:

  • Patent attorneys
  • In-house lawyers
  • Private practice lawyers
  • Patent agents and consultants

Enrol or reserve

The Drafting Effective Pharmaceutical Patents course will cover:

Introductory summary of the course

  • Overview of the programme
  • Patentability basics

Drafting primary patents – small molecules

  • Protecting pharmaceutical compositions
  • Protecting methods of treatment
  • Protecting medical use claims (first, second and Swiss-type)

Drafting primary patents – biologics

  • Drafting sequence disclosures
  • Protecting antibodies, stem cells and microorganisms
  • Drafting generic and species claims
  • Drafting functional claim language
  • Protecting gene therapy inventions

Primary patents workshop

  • Selection inventions
  • Drafting claims for infringement
    • Distilling down the invention disclosure
    • Patenting later developments
  • Practical examples and drafting exercises

Drafting with a focus towards interplay with regulatory issues

  • Patent term extension and SPCs
  • Regulatory issues and data protection – drafting to ‘follow the label’
  • The ANDA litigation process and enforcement of listed patents
  • Overlay of patent protection with FDA exclusivity – the FDA Orange Book
  • Strategies for protecting biologics

Data needed to support patent applications

  • What data must be included?
  • When must the data be included?
  • Consideration of post-filing date data
  • US written description
  • The importance of correct data – avoiding inequitable conduct

Secondary patents

  • Protecting dosage regimes, modes of administration, patient groups
  • Protecting polymorphs (crystals, enantiomers, salts)
  • Protecting metabolites
  • Protecting new formulations
  • Protecting process patents
  • Protecting methods of diagnosis and surgery

Secondary patents workshop

  • Establishing patentability: inventive step vs non-obviousness
  • Strategies for using post-filing evidence
  • Practical examples and drafting exercises

Enrol or reserve

Amanda Murphy

Dr. Amanda Murphy is a Partner in Finnegan’s Washington, DC Office and focuses her practice on strategic client counseling, portfolio management, and patent prosecution for a range of clients, including small startup companies, research foundations, and large biotechnology and pharmaceutical companies.
Amanda provides patentability opinions, prepares new patent applications, prosecutes U.S. and foreign applications, and represents appellants before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO). She has experience in prosecuting inter partes and ex parte reexamination applications, reissue applications, and patent term extension applications for approved pharmaceuticals, including obtaining supplemental protection certificates in Europe. In addition to her patent counseling and prosecution practice, Amanda also routinely represents petitioners and patent owners in inter partes review (IPR) and post grant review (PGR) proceedings before the PTAB. As part of that practice, Amanda works with experts to develop technical and legal bases for challenging or defending issued patents, and manages the preparation of substantive written submissions. She also provides strategic advice and pre-litigation analysis and prepares freedom-to-operate, enforceability, and infringement opinions.

More details

Maeve O'Flynn

Maeve O’Flynn is a European and UK patent attorney with more than a decade of in-house experience, having worked at some of the world’s largest multinational corporations in the oil and chemical industries. She has worked for a range of clients, from startups to multinationals, covering diverse technologies such as cosmetics, sustainable chemistry, and catalysis.

Maeve has helped clients develop commercially relevant intellectual property strategies. This includes developing and managing global patent portfolios, provisioning advice regarding trade secrets and defensive publications, and negotiating collaboration and licensing agreements.

Maeve has extensive experience preparing and prosecuting patent applications, from the initial invention harvesting sessions through to achieving allowance. She works with clients to assess and value their patent portfolios, and to develop filing strategies that support their commercial aims. She also represents clients at oral proceedings before the European Patent Office, representing both patentee and opponent.

More details

Alissa Lipton

Alissa Lipton’s practice involves representing biotechnology and pharmaceutical companies in patent proceedings in district courts, before the U.S. Court of Appeals for the Federal Circuit, and before the U.S. Patent and Trademark Office (USPTO). Her practice also involves strategic client counseling, including due diligence and opinion work, and portfolio management.

Alissa has over a decade of experience representing companies in patent litigation, from pre-litigation analysis through appeal to the Federal Circuit. She also provides strategic counsel to clients in technologies including therapeutic antibodies, CRISPR, antisense technologies, diagnostics, and small molecules. Alissa’s practice includes due diligence, freedom-to-operate, enforceability, and infringement assessments.

Alissa served at the Federal Circuit as a law clerk for the Honorable Alvin A. Schall. She has represented veterans before the U.S. Court of Appeals for Veterans Affairs.

More details

Victoria Randall

Victoria Randall is a chartered UK patent attorney and a European patent attorney. With a background in biomedical sciences, she works with a diverse portfolio of clients, including global pharmaceuticals and start-up biotechnology companies.

Victoria entered the patent profession in 2009 and joins Finnegan having previously worked for two large UK firms. She has acquired extensive experience in a broad range of life sciences subject matter. Her areas of interest include antibody technologies, antisense therapeutics, blood products, vaccines, gene manipulation, and stem cell culture methods.

Victoria enjoys all aspects of prosecution, including drafting, filing, examination, and grant procedures. She has experience with oppositions and appeals, representing both patentee and opponent at Oral Proceedings before the European Patent Office (EPO). She has managed large, complex portfolios protecting high-value pharmaceuticals. Victoria has experience prosecuting supplementary protection certificates and has been involved in litigation proceedings before the UK High Court.

Victoria has a first-class degree in Biomedical Sciences from The University of Sheffield and a Ph.D. from University College London. She conducted research at the Institute of Child Health at Great Ormond Street Hospital, where she focused on the genetic interactions underlying two congenital syndromes.

More details

Sara Leiman

Sara Leiman, PhD, is an associate in Finnegan LLP’s Boston office. Sara works with domestic and international clients across the life sciences on global patent prosecution, strategic counselling, due diligence, and validity and infringement opinions. She writes and speaks regularly on topics in intellectual property--particularly patent eligibility requirements, case law, and patent office guidance in the US--and co-authored and co-edited the book Patent Subject Matter Eligibility: A Global Guide. 

More details

James Masters

James focuses on patent prosecution, opinions and counseling, patent mapping, and patent litigation in the biotechnology, chemical, pharmaceutical, and medical device fields. His experience includes prosecution before the USPTO and in multiple foreign jurisdictions, performing patentability, invalidity, and freedom-to-operate analyses, and assisting with litigation before the U.S. International Trade Commission (ITC). He has a broad range of technical experience in the areas of organic and medicinal chemistry. Prior to joining Finnegan, he was a senior scientist in the chemical development group of Boehringer Ingelheim, where he developed robust and scalable chemical processes to support deliveries of pharmaceutical candidates.

James’s doctoral research concerned the development of new methods for the synthesis of small molecules, including biologically active natural products and pharmaceuticals. He holds a doctorate in chemistry from Stanford University

More details

Jamie Barcombe

Jamie Barcombe is a part-qualified UK and European patent attorney with a background in biotechnology. His experience extends to drafting, prosecuting and opposing European patent applications directed to a wide array of technologies, including nucleotide therapies, stem cells and biomarkers.  Jamie is adept in patent drafting, prosecution, and opposition, and providing strategic advice to clients ranging from global pharmaceutical companies to start-ups. He has experience managing international portfolios for clinical and pre-clinical candidates and pursuing protection for the candidates themselves in addition to their medical uses, manufacturing methods, and patient subgroups.  Jamie’s technical expertise spans the life sciences, covering biologics, biotechnology, clean energy, food and beverage, textiles and pharmaceuticals. He previously worked in research and development (R&D) for a multinational pharmaceutical company and practiced intellectual property management for a world-leading animal health institute, as well as conducted academic research investigating the delivery of therapeutic nucleotides.

More details

NEW higher discounts for multiple bookings - bring your colleagues to make your training budget go further:

  • 30% off the 2nd delegate*
  • 40% off the 3rd delegate*
  • 50% off the 4th delegate*

Please contact us for pricing if you are interested in booking 5 or more delegates

3-6 September 2024

Live online

13:30-17:00 UK (London) (UTC+01)
14:30-18:00 Paris (UTC+02)
08:30-12:00 New York (UTC-04)
Course code 15195

  • GBP 999 1,199
  • EUR 1,439 1,719
  • USD 1,647 1,959

Until 30 Jul

View basket 

Not ready to book yet?

for 7 days, no obligation

* Early booking discounts may not be combined with other discounts or offers. As such, the discounts for 2nd/3rd/4th delegates are based on the full price; and apply only when booking multiple delegates on the same date.

Reviews of IPI's Drafting Effective Pharmaceutical Patents training course

A very good webinar overall and felt very worthwhile. I am really glad that I attended. After the first day the sessions were livelier, and the polls added a little extra dimension to recap and tease out some of the points made in the presentations. The discussion between the EU and US based presenters on points of divergence worked really well and made the sessions less static and more engaging.

Nov 1 2022

Angela King
Patent Attorney, Croda Europe Limited


  • Alk Abello
  • Budde Schou
  • Budde Schou A/S
  • Genmab AS
  • Hoiberg A/S
  • Leo Pharma A/S
  • Novo Nordisk A/S

United Kingdom

  • Adamson Jones
  • CMS Cameron McKenna Nabarro Olswang LLP
  • Croda Europe Limited
  • Forresters
  • Nordic Pharma
  • UCB Celltech Ltd


  • IPR Partners Ltd
  • Kolster OY AB


  • Grunenthal GmbH
  • MorphoSys AG


  • Strom & Gulliksson AB
  • Valea AB


  • Fundacao Biominas


  • Xellia

Czech Republic

  • PatentEnter s.r.o


  • Chinoin Zrt - member of sanofi-aventis Group


  • Sun Pharmaceutical Industries Ltd.


  • C2 Pharma




  • Raul Cesar Ferreira (Herd) SA


  • Nestec SA

Enrol or reserve

Run Drafting Effective Pharmaceutical Patents Live online for your team

2 days

Typical duration

Pricing from:

  • GBP 800
  • Per attendee, based on 10 attendees
  • Course tailored to your requirements
  • At your choice of location, or online


We can customise this course to your requirements and deliver it on an in-house basis for any number of your staff or colleagues.

Contact our in-house training experts Aleksandra Beer and Yesim Nurko to discuss your requirements:

Multiple colleagues? See above for details of our discounts for 2, 3, or 4 delegates. For more, talk to one of our training experts to discuss how to:

Run this course conveniently and cost-effectively in-house for your staff and colleagues

Aleksandra Beer

Aleksandra BEER
Training expert

Yesim Nurko

Training expert

+44 (0)20 7749 4749